AGENT SHOWING ANTIAGGREGATION ACTIVITY Russian patent published in 1996 - IPC

FIELD: medicine, diabetology. SUBSTANCE: proposed agent is 9-diethylaminoethyl-2,3-dihydroimidazo[1,2-a] benzimidazole dihydrochloride showing hypoglycaemic activity. At the dose single dose 25 mg/kg compound decreases glucose content in animal with alloxane diabetes by 38% and after 10 day administration (25 mg/kg, every day) hypoglycaemic effect is increased by 1.5 fold. Hypoglycaemic potency of compound is equal with gliclazide, it exceeds that of maninil by 1.5 time and that of adebite by 2.4 times that are the known sugar-decreasing drugs. Duration of sugar-decreasing effect of proposed preparation corresponds with that of hypoglycaemic action of sulfonylurea derivatives, - gliclazide and maninil and exceeds this index of butylbiguanide derivative - adebite - by 3 times. Sugar-decreasing effect of substance is due to its stimulating effect on insulin secretion from β-cells of pancreas and potentiating (by 2.7 times) and prolonged (by 1.5 times) influence on hypoglycaemic action of this hormone. Compound is an active inhibitor of platelet aggregation and exceeds this effect of gliclazide and acetylsalicylic acid by 37 and 16.4 times, respectively, in vitro experiments. Antiaggregation effect of compound on intravessel platelet aggregation exceeds that of acetylsalicylic acid by 23.3 times. Proposed compound can be used for diabetes mellitus treatment, in part, at complicated states and used orally. EFFECT: increased effectiveness of new proposed antidiabetic agent. 3 tbl